San Diego, CA – [5th June 2025] — Liferna, a mission-driven company dedicated to developing life-changing medicines to treat autoimmune and fibrotic diseases with no cure, today announced its official launch from stealth mode.
“We are excited to introduce Liferna to the world,” said Dushyant Varshney, PhD, Chairman, CEO and Founder. “Our experienced founding team is dedicated to leveraging deep scientific expertise and an innovative platform technology to drive the development of novel targeted products that can have a transformational impact on our patients’ lives.
As part of our launch, we are proud to announce our lead product LFR-201 as a potential new treatment for systemic sclerosis corroborated by an exclusive in-licensed technology from the University of Michigan. LFR-201 with validated pre-clinical data has an accelerated path to enter clinical development in 2025. In parallel, we are actively building a broader pipeline of candidates to address other complex diseases.”
Liferna is grateful for the support of our investors, advisors, collaborators and partners who share the same vision of launching safe and effective first-in-class products globally to treat patients with autoimmune and fibrotic diseases.
To learn more about Liferna and follow our progress, continue to visit https://liferna.com/ and follow us on LinkedIn.